LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference

03 Apr 2024
www.biospace.com
Phase 3Clinical Result
CINCINNATI--(BUSINESS WIRE)-- LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, LDL-cholesterol lowering, third-generation PCSK9 inhibitor, today announced that David Cory, CEO, and Evan Stein, MD, PhD, COO / CSO, will participate in a virtual fireside chat at the Piper Sandler Virtual Cardio Day on April 10, 2024 at 10:30 AM ET. Participants will include leadership from presenting companies and highlights from presentations at the American College of Cardiology 2024 in Atlanta, Georgia. REGISTER HERE A live webcast of the presentation will be available on the LIB Therapeutics website at . About Lerodalcibep Lerodalcibep, a novel, potent, small binding protein, third-generation PCSK9 inhibitor, has been developed as a more convenient, once-monthly dose in a small injection volume and with long-ambient stability. Combined with sustained LDL-C reductions demonstrated in clinical trials, lerodalcibep is expected to expand treatment options for the millions of patients around the world with atherosclerotic cardiovascular disease (ASCVD), and those at very high and high risk for ASCVD, including the 30 million individuals with more severe inherited high-cholesterol called familial hypercholesterolemia (FH). The global Phase 3 LIBerate program enrolled over 2,700 patients and included a diverse population of patients with CVD, without CVD at very high and high risk for CVD, including heterozygous and homozygous familial hypercholesterolemia (FH). Key registration placebo-controlled trials included Lerodalcibep once-monthly for up to 52 weeks, and over 2,400 patients continued in the 72-week open-label extension trial. LIB is preparing a biologics license application (BLA) for Lerodalcibep and plans for regulatory submission in 2024. About LIB Therapeutics Inc. LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients with cardiovascular disease and the 30 million individuals with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents. For more information, please visit: .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.